공지사항

Tumor Treating Fields Mesothelioma

Fields peritoneal mesothelioma treatment treating tumors, a new form of therapy, uses alternating electric field to slow the growth of cancer. It is used in combination with chemotherapy to treat pleural cancer.

The FDA approved TTFields in conjunction with pemetrexed and Cisplatin in the year 2019 following the success of the STELLAR trial. Patients can ask their mesothelioma specialist to prescribe this treatment.

Disrupting Cell Division

TTFields utilizes different electrical fields that disrupt cancer cell proteins and stop the cells from dividing. This prevents mesothelioma tumor cells from growing or spreading to other organs within the body. The TTFields stimulate the release of proteins that kill cancerous cells and assist the immune system in fighting mesothelioma tumours.

During treatment the patient wears an insulated device that is small in size. pads that are bonded to the skin. The device is able to deliver an electrical current that is low-intensity and the patient is able to control how much treatment they receive. A mesothelioma session lasts about 30 minutes. Patients can receive the TTFields Treatment multiple times a day.

A TTFields research study published in 2021 found that the electrical field intensity of 100 to 300 Kilohertz could stop the division of cancer cells and cause them to die. The study covered a variety of cancerous cells and found that electrical fields killed all of them, regardless of their cellular structure.

The study's authors recommended the use of TTFields with chemotherapy for mesothelioma. Novocure's TTFields product, NovoTTF-100L was approved by the FDA in the year 2019 to treat pleural mesothelioma that is not resectable. It is now accessible through mesothelioma doctors at certified medical centers across the U.S., including the West Cancer Center in Memphis. The NovoTTF 100L device, also known as Optune Lua has been used to treat mesothelioma when it is combined with platinum-based chemotherapy and pemetrexed. Mesothelioma victims have reported an extended survival time when the TTFields treatment is combined with chemotherapy.

Another study, which was published in "Lung Cancer", reported that TTFields therapy is effective with chemotherapy. Researchers discovered that the combination of chemotherapy and TTFields significantly reduced the number of malignant mesothelioma cancer cells in animal models. The study also revealed that combing these treatments boosted the production proteins that kill mesothelioma cancerous cells and reduce the amount or cancerous DNA that is found in your body.

The TTFields procedure is a relatively recent treatment and many mesothelioma specialists do not recommend it for patients with pleural mesothelioma alternative treatment - read the article, malignant mesothelioma. However, patients may still have access to this treatment option through clinical trials or mesothelioma centres that have been certified by Novocure.

Stalling Tumor Growth

When mesothelial cancer cells multiply and outlive their normal lifespan, they become mutated and may result in an overabundance which grows and expands throughout the body. Tumor treating fields stop mesothelioma tumors from spreading and growing by blocking mesothelial cells from duplicated.

The TTFields device is worn on the chest as an armband and generates a series of electrical fields that can alter proteins which kill cancerous cells, and slow down tumor growth. The device comes with insulated pads that stick to the skin. Patients or health care professionals can apply them at home.

Doctors recommend mixing TTFields with chemotherapy to achieve the best results. The combination increases production of proteins that destroy cancerous cells, and reduces cancer cells' capacity to repair DNA damage from chemotherapy drugs. This makes chemotherapy drugs perform more effectively and improves the survival rate in mesothelioma patients.

In the most recent STELLAR trial, the combination of TTFields therapy and chemotherapy significantly improved survival for mesothelioma sufferers. In the year 2019, the FDA approved the NovoTTF 100L System, now marketed under Optune Lua for use with pemetrexed, Cisplatin, or carboplatin, as a first-line treatment of malignant pleural melanoma that is not surgically resectable.

Researchers have discovered that TTFields therapy is effective against mesothelioma by interrupting cell division. The TTFields treatment causes cancer cells to split apart in a mitosis process. The cellular debris gets trapped in the surrounding tissues and hinders the growth of new tissue. Mitosis stops mesothelioma tumor cells from repair of damaged genetic material and Pleural Mesothelioma Alternative Treatment makes them more prone to radiation therapy.

The TTFields therapy can also reduce the flow of blood from tumors by suppression of vascular endothelial growth factor (VEGF) and the rise of hypoxia-inducible factor-1 alpha or HIF-1a. HIF-1a is associated with cancer cells angiogenesis.

If you've been diagnosed with mesothelioma or other cancers, talk with your doctor about whether TTFields is a good option for you. Many mesothelioma specialists are working with Novocure on clinical trials to test the efficacy of this new treatment. Contact a Novocure certified specialist at one of the more than 1,300 U.S. Treatment Centers to find out more about the mesothelioma treatment options with TTFields.

Killing Tumor Cells

Tumor treating fields (TTFields) disrupt cell division by sending electrical signals through the body to destroy cancer cells. TTFields are low-intensity and intermediate frequency electrical fields that alternatingly are targeted at cancerous cells, without harming healthy ones. They also hinder DNA repair and increase cell defenses, making it harder for cancerous cells to survive. TTF is non-invasive, and has only minor side effects.

Scientists believe TTFields stop mitosis - the process by which a cell divides into two identical new cells. Normal cells have mechanisms to restrict mitosis. However cancerous tumors of malignancy are able to break these limitations and multiply at an accelerated rate. TTFields interfere with this process by blocking the signals that regulate the growth of mesothelioma cells. In the STELLAR study, TTFields when combined with chemotherapy significantly increased survival rates in mesothelioma patients. Mesothelioma patients who received TTFields along with maintenance cycles of chemotherapy lived an average of six months longer than those who just received chemotherapy.

A separate study has found that TTFields could boost the effectiveness of certain chemotherapy drugs, known as platinum-based therapies. These platinum-based treatments eliminate mesothelioma cells by targeting the mitochondria, which is where cancerous cells get their energy from. When TTFields is combined with these chemotherapies, the combination can result in higher levels DNA damage and faster death of cancer cells.

In certain instances, TTFields can also enhance the effects of radiation therapy. Scientists have observed that combining TTFields with radiation therapy could result in an "synergistic effect." This means that the combined treatments increase the sensitivity of mesothelioma cells to radiation.

At present, TTFields can only be available at certain mesothelioma centres. However, a mesothelioma expert can determine whether you may be suitable for this treatment. If you do qualify an attorney for mesothelioma can assist you in gaining access to treatments that could include TTFields alongside chemotherapy. A mesothelioma attorney can help veterans get VA-covered treatment.

Side Effects

The TT fields therapy disrupts the cancer cells by creating an electrical field that hinders their ability to divide. This can slow the growth of tumors and prevent them from spreading to other parts of the body. The TT Fields device is noninvasive. It does not cause discomfort or damage to surrounding tissue. This is different than traditional chemotherapy, which involves intravenous injections or radiation, both of which can have serious side effects.

In an experiment in which patients were treated with a combination TT fields and temozolomide saw survival improvements similar to those who only received chemo. Doctors attributed the improved survival to TT fields' ability to increase the efficacy of chemo and lessen the risk of the adverse effects.

Mesothelioma cells can mutate into cancerous cells and replicate uncontrollably to form tumors that infiltrate the organs of your body. By halting cell division, mesothelioma treatments like TT fields stop pericardial mesothelioma treatment cells from reproducing and hindering your body's normal functions.

During a mesothelioma trial patients with mesothelioma disease treatment who received TT fields along with chemotherapy had an average survival of 18.2 months. Patients who received TT fields, but not chemo had a survival rate of 12.1.

Tumor-treating fields can be applied to the pleura or the thin lining that surrounds your lungs, whether on your chest or abdominal wall. The device is small and can be worn for 18 hours a day even during sleep time. Patients can live their lives and continue working while undergoing treatment.

TT fields can be combined with conventional chemotherapy, immunotherapy, or other mesothelioma treatments. Mesothelioma patient interested in TT should discuss the option with their specialist. They can discuss the conditions for eligibility and the potential benefits for each patient's case.